ATE356148T1 - Antikörper die einen erythropoietinrezeptor aktivieren - Google Patents

Antikörper die einen erythropoietinrezeptor aktivieren

Info

Publication number
ATE356148T1
ATE356148T1 AT01111554T AT01111554T ATE356148T1 AT E356148 T1 ATE356148 T1 AT E356148T1 AT 01111554 T AT01111554 T AT 01111554T AT 01111554 T AT01111554 T AT 01111554T AT E356148 T1 ATE356148 T1 AT E356148T1
Authority
AT
Austria
Prior art keywords
antibodies
activate
erythropoietin receptor
erythropoietin
erythropiesis
Prior art date
Application number
AT01111554T
Other languages
English (en)
Inventor
Steven G Elliott
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE356148T1 publication Critical patent/ATE356148T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT01111554T 1994-07-26 1995-07-26 Antikörper die einen erythropoietinrezeptor aktivieren ATE356148T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/280,864 US5885574A (en) 1994-07-26 1994-07-26 Antibodies which activate an erythropoietin receptor

Publications (1)

Publication Number Publication Date
ATE356148T1 true ATE356148T1 (de) 2007-03-15

Family

ID=23074937

Family Applications (2)

Application Number Title Priority Date Filing Date
AT95927476T ATE209218T1 (de) 1994-07-26 1995-07-26 Antikörper die den erythropoetinrezeptor aktivieren
AT01111554T ATE356148T1 (de) 1994-07-26 1995-07-26 Antikörper die einen erythropoietinrezeptor aktivieren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT95927476T ATE209218T1 (de) 1994-07-26 1995-07-26 Antikörper die den erythropoetinrezeptor aktivieren

Country Status (17)

Country Link
US (5) US5885574A (de)
EP (2) EP1146056B1 (de)
JP (2) JP3225493B2 (de)
CN (1) CN1158134A (de)
AT (2) ATE209218T1 (de)
AU (1) AU697369B2 (de)
CA (1) CA2195868A1 (de)
DE (2) DE69524102T2 (de)
DK (2) DK0773962T3 (de)
ES (2) ES2283355T3 (de)
IL (1) IL114717A0 (de)
MX (1) MX9700553A (de)
NZ (1) NZ290689A (de)
PT (2) PT1146056E (de)
SI (1) SI0773962T1 (de)
WO (1) WO1996003438A1 (de)
ZA (1) ZA956215B (de)

Families Citing this family (192)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885574A (en) * 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
AU6163196A (en) * 1995-06-07 1996-12-30 Smithkline Beecham Corporation Method for obtaining receptor agonist antibodies
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US6346390B1 (en) * 1996-03-08 2002-02-12 Receptron, Inc. Receptor derived peptides involved in modulation of response to ligand binding
WO1997048729A1 (en) * 1996-06-21 1997-12-24 Arris Pharmaceutical Corporation Bivalent molecules that form an activating complex with an erythropoietin receptor
US6103879A (en) * 1996-06-21 2000-08-15 Axys Pharmaceuticals, Inc. Bivalent molecules that form an activating complex with an erythropoietin receptor
US6221608B1 (en) * 1997-01-22 2001-04-24 Ortho Pharmaceutical Corporation Methods for identifying erythropoietin receptor binding protein
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
ATE395362T1 (de) * 1997-09-11 2008-05-15 Chugai Pharmaceutical Co Ltd Monoklonale antikörper zur apoptosis-induzierung
US7531643B2 (en) * 1997-09-11 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
US7621901B2 (en) * 1999-02-10 2009-11-24 First Quality Products, Inc. Disposable pant type absorbent article having improved multifold fastening system and method of making same
EP1167388A4 (de) * 1999-03-10 2002-05-29 Chugai Pharmaceutical Co Ltd Apoptose induzierendes einzelsträngiges fv
US7696325B2 (en) * 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
EP1169352A4 (de) * 1999-04-14 2005-05-04 Smithkline Beecham Corp Antikörper gegen den erythropoietin-rezeptor
CA2404431C (en) * 2000-03-27 2011-06-07 Thomas Jefferson University Guanylyl cyclase c in the detection of stomach and esophageal cancers
EP1275000A4 (de) * 2000-04-05 2005-06-15 Jong Y Lee Nachweis von erythropoietin und dem erythropoietinrezeptor
US20040058393A1 (en) * 2000-04-17 2004-03-25 Naoshi Fukishima Agonist antibodies
CN100364612C (zh) * 2000-10-20 2008-01-30 中外制药株式会社 低分子化的激动剂抗体
AU1091802A (en) * 2000-10-20 2002-04-29 Chugai Pharmaceutical Co Ltd Degraded agonist antibody
RU2408606C2 (ru) * 2000-10-20 2011-01-10 Тугаи Сейяку Кабусики Кайся Соединение - агонист тро
US20040242847A1 (en) * 2000-10-20 2004-12-02 Naoshi Fukushima Degraded agonist antibody
CA2424364A1 (en) * 2000-10-20 2003-04-01 Chugai Seiyaku Kabushiki Kaisha Degraded tpo agonist antibody
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
AU3400102A (en) 2000-12-05 2002-06-18 Alexion Pharma Inc Rationally designed antibodies
ES2261458T3 (es) * 2001-07-26 2006-11-16 Tagra Biotechnologies Ltd Derivados estabilizados del aciddo ascorbico 3-fosfato.
AU2002325712C1 (en) 2001-08-30 2008-07-31 Stem Cell Therapeutics Inc. Differentiation of neural stem cells and therapeutic use theeof
AR036401A1 (es) * 2001-09-14 2004-09-08 Stem Cell Therapeutics Inc Incremento de la cantidad de celulas madre neuronales inducido por prolactina.
AU2002325710A1 (en) * 2001-09-18 2003-04-01 Stem Cell Therapeutics Inc. Effect of growth hormone and igf-1 on neural stem cells and therapeutic application
US7053050B2 (en) * 2001-11-02 2006-05-30 Yoshiko Yasuda Preventives/remedies for proliferative organ diseases chronic arthritic diseases, hypertrophic scar or keloid
US7300915B2 (en) 2002-06-05 2007-11-27 The Regents Of The University Of California Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain
EP1546198A1 (de) * 2002-07-31 2005-06-29 Stem Cell Therapeutics Inc. Verfahren zur verbesserung der proliferation, der differenzierung und des berlebens von neuralen stammzellen unter verwendung von pituitary adenylate cyclase activating polypeptide (pacap)
AU2002325432A1 (en) * 2002-08-02 2004-02-23 Alexandr Mikhailovich Dygay Medicinal agent and method for curing pathological syndrome associated to hemodiscrasia
US20040076620A1 (en) * 2002-09-03 2004-04-22 Donnie Rudd Method of repairing primate mammalian tissue
US20040076605A1 (en) * 2002-09-03 2004-04-22 Donnie Rudd Method of regenerating human tissue
US20040044300A1 (en) * 2002-09-03 2004-03-04 Donnie Rudd Method of replenishing cells damaged by treatment for cancer
US20040043009A1 (en) * 2002-09-03 2004-03-04 Donnie Rudd Method of repairing primate mammalian tissue
US20040077985A1 (en) * 2002-09-03 2004-04-22 Donnie Rudd Method of replenishing cells damaged by treatment for cancer
US20040042997A1 (en) * 2002-09-03 2004-03-04 Donnie Rudd Method of regenerating human tissue
JPWO2004033499A1 (ja) * 2002-10-11 2006-02-09 中外製薬株式会社 細胞死誘導剤
US20040071694A1 (en) * 2002-10-14 2004-04-15 Devries Peter J. Erythropoietin receptor binding antibodies
US7396913B2 (en) * 2002-10-14 2008-07-08 Abbott Laboratories Erythropoietin receptor binding antibodies
TWI320716B (en) * 2002-10-14 2010-02-21 Abbott Lab Erythropoietin receptor binding antibodies
ES2320754T3 (es) * 2002-10-22 2009-05-28 Waratah Pharmaceuticals, Inc. Tratamiento de la diabetes.
KR100473172B1 (ko) * 2002-11-27 2005-03-10 씨제이 주식회사 인간 에리스로포이에틴과 변형 에리스로포이에틴을 모두인식하는 모노클로날 항체 및 그를 생산하는 융합세포주
JP2004279086A (ja) * 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
US20070003556A1 (en) * 2003-03-31 2007-01-04 Masayuki Tsuchiya Modified antibodies against cd22 and utilization thereof
CA2521979A1 (en) * 2003-04-09 2004-10-28 University Of Utah Research Foundation Compositions and methods related to production of erythropoietin
SI1644363T1 (sl) 2003-05-30 2012-07-31 Gemin X Pharmaceuticals Canada Inc Triheterociklične spojine sestavki in postopki za zdravljenje raka
US20070111932A1 (en) * 2003-07-31 2007-05-17 Stem Cell Therapeutics Inc. Method of enhancing and/or inducing neuronal migration using erythropoietin
TW200530266A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Method of reinforcing antibody activity
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
US20070281327A1 (en) * 2003-12-12 2007-12-06 Kiyotaka Nakano Methods of Screening for Modified Antibodies With Agonistic Activities
AU2004297109A1 (en) * 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha Cell death inducing agent
DK1709081T3 (da) * 2004-01-16 2011-06-06 Regeneron Pharma Fusionspolypeptider, der kan aktivere receptorer
US8298532B2 (en) * 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
CA2556266A1 (en) * 2004-02-13 2005-08-25 Stem Cell Therapeutics Corp. Use of luteinizing hormone (lh), and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
US20050227289A1 (en) * 2004-04-09 2005-10-13 Reilly Edward B Antibodies to erythropoietin receptor and uses thereof
US20060018902A1 (en) * 2004-04-09 2006-01-26 Reilly Edward B Antibodies to erythropoietin receptor and uses thereof
US20080038265A1 (en) * 2004-04-09 2008-02-14 Reilly Edward B Antibodies to Erythropoietin Receptor and Uses Thereof
US20050255112A1 (en) * 2004-05-17 2005-11-17 Lee Jong Y Compositions and methods for preventing erythropoietin-associated hypertension
CA2582567A1 (en) 2004-10-07 2006-04-13 Stem Cell Therapeutics Corp. Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds
WO2006089397A1 (en) * 2005-02-22 2006-08-31 Gemin X Biotechnologies Inc. Methods for treating arthritis using triheterocyclic compounds
EP1870458B1 (de) * 2005-03-31 2018-05-09 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2-STRUKTURISOMERE
US20090022687A1 (en) * 2005-05-18 2009-01-22 Chugai Seiyaku Kabushiki Kaisha Novel Pharmaceuticals That Use Anti-HLA Antibodies
CN101262885B (zh) 2005-06-10 2015-04-01 中外制药株式会社 含有sc(Fv)2的药物组合物
KR101367544B1 (ko) * 2005-06-10 2014-02-26 추가이 세이야쿠 가부시키가이샤 메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용
AU2006297041A1 (en) * 2005-09-27 2007-04-05 Stem Cell Therapeutics Corp. Oligodendrocyte precursor cell proliferation regulated by prolactin
JP2009530234A (ja) * 2006-03-17 2009-08-27 ステム セル セラピューティクス コーポレイション 神経変性疾患の治療のためのｌｈまたはｈｃｇ、およびｅｐｏについての投与レジメン
EP2007813A2 (de) * 2006-04-14 2008-12-31 Amgen Inc. Agonist-erythropoietin-rezeptor-antikörper
CA2649384A1 (en) * 2006-04-14 2007-10-25 Amgen Inc. Erythropoietin receptor agonists
US20080051400A1 (en) * 2006-07-06 2008-02-28 Gemin X Biotechnologies Inc. Methods for treating or preventing anemia or thrombocytopenia using a triheterocyclic compound
BRPI0714209A2 (pt) * 2006-07-13 2014-06-24 Chugai Pharmaceutical Co Ltd Induzidor de morte celular
WO2008097461A2 (en) 2007-02-02 2008-08-14 Amgen Inc Hepcidin and hepcidin antibodies
CL2008000719A1 (es) * 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
CA2701032C (en) 2007-09-27 2021-01-26 Amgen Inc. Pharmaceutical formulations
US8796206B2 (en) 2007-11-15 2014-08-05 Amgen Inc. Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
WO2009094551A1 (en) 2008-01-25 2009-07-30 Amgen Inc. Ferroportin antibodies and methods of use
ES2487846T3 (es) 2008-05-01 2014-08-25 Amgen, Inc. Anticuerpos anti-hepcindina y métodos de uso
GB0812277D0 (en) * 2008-07-04 2008-08-13 Fusion Antibodies Ltd Antibody and uses thereof
JP2012500818A (ja) * 2008-08-28 2012-01-12 エフ．ホフマン−ラ ロシュ アーゲー ヒトｅｐｏ受容体に対する抗体
CN104922669A (zh) 2008-11-13 2015-09-23 通用医疗公司 用于通过调整bmp-6来调节铁稳态的方法和组合物
US9221909B2 (en) 2009-01-15 2015-12-29 Hoffmann-La Roche Inc. Antibodies against human EPO receptor
CN102655872B (zh) 2009-08-13 2016-01-20 阿塞勒隆制药公司 Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平
AU2010310457B2 (en) 2009-10-23 2015-07-02 Amgen Inc. Vial adapter and system
RS54291B2 (sr) 2010-06-07 2023-12-29 Amgen Inc Uređaj za isporuku lekova
MX341790B (es) 2011-03-31 2016-09-02 Amgen Inc Adaptador de viales y sistema.
CA3145238A1 (en) 2011-04-20 2012-10-26 Amgen Inc. Autoinjector apparatus
US8623666B2 (en) 2011-06-15 2014-01-07 Hoffmann-La Roche Inc. Method for detecting erythropoietin (EPO) receptor using anti-human EPO receptor antibodies
CA2851521C (en) 2011-10-14 2020-09-22 Amgen Inc. Injector and method of assembly
BR122019023174B1 (pt) 2011-10-17 2021-02-23 Acceleron Pharma, Inc Uso de um polipeptídeo para a fabricação de um medicamento paratratar anemia associada à esplenomegalia
CA2890217C (en) 2012-11-02 2021-07-20 Yifu FANG Activin-actrii antagonists and uses for treating bone and other disorders
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
AU2013348071B2 (en) 2012-11-21 2018-05-24 Amgen Inc. Drug delivery device
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
EP2968760B1 (de) 2013-03-15 2024-01-03 Amgen Inc. Medikamentenkassette, autoinjektor und autoinjektorsystem
WO2014143815A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
CA2904357C (en) 2013-03-15 2020-09-22 Intrinsic Lifesciences Llc Anti-hepcidin antibodies and uses thereof
TWI592183B (zh) 2013-03-15 2017-07-21 安美基公司 本體輪廓可調適之自動注射器裝置
LT2976117T (lt) 2013-03-22 2021-02-25 Amgen Inc. Purkštuvas ir surinkimo būdas
US11427627B2 (en) 2013-09-05 2022-08-30 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
BR112016008946B1 (pt) 2013-10-24 2022-12-27 Amgen Inc Injetores e método para montar os injetor
EP3501575B1 (de) 2013-10-24 2021-12-01 Amgen Inc. Arzneimittelabgabesystem mit temperaturempfindlicher steuerung
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
AP2016009549A0 (en) 2014-04-18 2016-11-30 Acceleron Pharma Inc Methods for increasing red blood cell levels and treating sickle-cell disease
EP3139977B1 (de) 2014-05-07 2021-02-17 Amgen Inc. Autoinjektor mit stossabsorbierenden elementen
CA2949237C (en) 2014-05-16 2022-08-23 Amgen Inc. Assay for detecting th1 and th2 cell populations
SG11201609966SA (en) 2014-06-03 2016-12-29 Amgen Inc Drug delivery system and method of use
EP3154566B1 (de) 2014-06-13 2022-08-03 Acceleron Pharma Inc. Actrii antagonist zur behandlung oder prävention eines hautulzers in einem patienten mit anämie
WO2016018883A1 (en) * 2014-07-29 2016-02-04 The Board Of Trustees Of The Leland Stanford Junior University Tuning dimeric receptor signaling with extracellular ligands that alter receptor orientation and proximity upon binding
US10323088B2 (en) 2014-09-22 2019-06-18 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
MX2021014323A (es) 2014-10-14 2023-02-02 Amgen Inc Dispositivo de inyección de fármaco con indicadores visuales y audibles.
WO2016069925A1 (en) 2014-10-30 2016-05-06 Acceleron Pharma Inc. Methods and compositions using gdf15 polypeptides for increasing red blood cells
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
EP4233889A3 (de) 2014-12-03 2023-10-11 Celgene Corporation Activin-actrii-antagonisten und verwendungen davon zur behandlung von myelodysplastischem syndrom
EP3689394A1 (de) 2014-12-19 2020-08-05 Amgen Inc. Arzneimittelabgabevorrichtung mit live-knopf oder benutzerschnittstellenfeld
EP3848072A1 (de) 2014-12-19 2021-07-14 Amgen Inc. Medikamentenabgabevorrichtung mit näherungssensor
EP3556411B1 (de) 2015-02-17 2021-06-30 Amgen Inc. Arzneimittelabgabevorrichtung mit vakuumunterstützter sicherung und/oder rückkopplung
EP3261690B1 (de) 2015-02-27 2021-12-15 Amgen Inc. Arzneimittelabgabevorrichtung mit nadelschutzmechanismus mit abstimmbarem widerstandsschwellwert gegenüber der bewegung des nadelschutzes
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
EP3370754A4 (de) 2015-11-04 2019-10-23 Acceleron Pharma Inc. Verfahren zur erhöhung der erythrozytenkonzentration und behandlung von ineffizienter erythropoiese
US11351308B2 (en) 2015-12-09 2022-06-07 Amgen Inc. Auto-injector with signaling cap
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
ES2814287T3 (es) 2016-03-15 2021-03-26 Amgen Inc Reducir la probabilidad de rotura de cristal en dispositivos de administración de fármaco
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
WO2017197222A1 (en) 2016-05-13 2017-11-16 Amgen Inc. Vial sleeve assembly
WO2017200989A1 (en) 2016-05-16 2017-11-23 Amgen Inc. Data encryption in medical devices with limited computational capability
WO2017209899A1 (en) 2016-06-03 2017-12-07 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
EP3478342A1 (de) 2016-07-01 2019-05-08 Amgen Inc. Arzneimittelabgabevorrichtung mit minimiertem teilebruchrisiko nach aufprallereignissen
WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
US20190218262A1 (en) 2016-09-15 2019-07-18 Acceleron Pharma Inc. Twisted gastrulation polypeptides and uses thereof
WO2018081234A1 (en) 2016-10-25 2018-05-03 Amgen Inc. On-body injector
AU2018210301A1 (en) 2017-01-17 2019-08-01 Amgen Inc. Injection devices and related methods of use and assembly
CA3048520A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
US11369736B2 (en) 2017-02-17 2022-06-28 Amgen Inc. Cannula insertion and retraction mechanisms
JP2020508803A (ja) 2017-03-06 2020-03-26 アムジエン・インコーポレーテツド 作動防止特徴部を備える薬物送達デバイス
SG11201908058UA (en) 2017-03-07 2019-09-27 Amgen Inc Needle insertion by overpressure
KR102619150B1 (ko) 2017-03-09 2023-12-27 암겐 인코포레이티드 약물 전달 장치용 삽입 메커니즘
MA47775A (fr) 2017-03-14 2020-01-22 Amgen Inc Contrôle des glycoformes afucosylées totales d'anticorps produits en culture cellulaire
JP2020511499A (ja) 2017-03-20 2020-04-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 赤血球生成刺激タンパク質のインビトロでの糖鎖改変のための方法
SI3600491T1 (sl) 2017-03-28 2023-11-30 Amgen Inc. Sistem in postopek za sestavljanja droga bata in brizge
US20200179524A1 (en) * 2017-04-25 2020-06-11 Lipoxen Technologies Limited Methods of treating multiple myeloma cancers expressing high levels of epo-receptor using psa-epo
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
CN110709121B (zh) 2017-06-08 2022-06-24 安进公司 扭矩驱动式药物递送装置
MX2019015472A (es) 2017-06-22 2020-02-19 Amgen Inc Reduccion del impacto/choque de la activacion del mecanismo.
WO2018237225A1 (en) 2017-06-23 2018-12-27 Amgen Inc. ELECTRONIC DRUG DELIVERY DEVICE COMPRISING A CAP ACTIVATED BY A SWITCH ASSEMBLY
EP3651832B1 (de) 2017-07-14 2023-12-13 Amgen Inc. Nadeleinführ-retraktionssystem mit doppeltorsionsfedersystem
MA49626A (fr) 2017-07-21 2020-05-27 Amgen Inc Élément d'étanchéité perméable aux gaz pour récipient à médicament et procédés d'assemblage
MA49676A (fr) 2017-07-25 2020-06-03 Amgen Inc Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé
EP3658203B1 (de) 2017-07-25 2022-08-31 Amgen Inc. Arzneimittelabgabevorrichtung mit getriebemodul und verwandtes verfahren zur montage
WO2019032482A2 (en) 2017-08-09 2019-02-14 Amgen Inc. HYDRAULIC-PNEUMATIC PRESSURE CHAMBER DELIVERY SYSTEM
EP3668567A1 (de) 2017-08-18 2020-06-24 Amgen Inc. Am körper tragbarer injektor mit sterilem klebepflaster
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
MA50611A (fr) 2017-10-04 2020-08-12 Amgen Inc Adaptateur d'écoulement destiné à un dispositif d'administration de médicament
WO2019070552A1 (en) 2017-10-06 2019-04-11 Amgen Inc. DRUG DELIVERY DEVICE COMPRISING A LOCKOUT ASSEMBLY AND ASSOCIATED ASSEMBLY METHOD
US11464903B2 (en) 2017-10-09 2022-10-11 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
MA50527A (fr) 2017-11-03 2020-09-09 Amgen Inc Système et approches pour stériliser un dispositif d'administration de médicament
EP3706830B1 (de) 2017-11-06 2024-08-07 Amgen Inc. Arzneimittelabgabevorrichtung mit positionierungs- und durchflussmessung
EP3707075A1 (de) 2017-11-06 2020-09-16 Amgen Inc. Füllabschlussanordnungen und zugehörige verfahren
CN111225696B (zh) 2017-11-10 2023-07-18 安进公司 用于药物递送装置的柱塞
AU2018368340B2 (en) 2017-11-16 2024-03-07 Amgen Inc. Door latch mechanism for drug delivery device
AU2018368338B2 (en) 2017-11-16 2024-07-25 Amgen Inc. Autoinjector with stall and end point detection
IL313983A (en) 2018-03-26 2024-08-01 Amgen Inc Fully fucose-free glycoforms of antibodies are produced in cell culture
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
MA53375A (fr) 2018-07-24 2021-06-02 Amgen Inc Dispositifs d'administration pour l'administration de médicaments
MA53379A (fr) 2018-07-24 2021-06-02 Amgen Inc Dispositifs d'administration pour l'administration de médicaments
US12115360B2 (en) 2018-07-24 2024-10-15 Amgen Inc. Hybrid drug delivery devices with grip portion
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
US12109389B2 (en) 2018-07-31 2024-10-08 Amgen Inc. Fluid path assembly for a drug delivery device
US20210346601A1 (en) 2018-09-24 2021-11-11 Amgen Inc. Interventional dosing systems and methods
AU2019350660B2 (en) 2018-09-28 2024-09-26 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
CN117159846A (zh) 2018-10-02 2023-12-05 安进公司 具有内部力传递的用于药物递送的注射系统
CA3112214A1 (en) 2018-10-05 2020-04-09 Amgen Inc. Drug delivery device having dose indicator
MA53912A (fr) 2018-10-15 2022-01-19 Amgen Inc Dispositif d'administration de médicament comprenant un mécanisme d'amortissement
MX2021002791A (es) 2018-10-15 2021-05-12 Amgen Inc Proceso de ensamblaje de plataforma para un dispositivo de administracion de farmacos.
EP3873563A1 (de) 2018-11-01 2021-09-08 Amgen Inc. Vorrichtung zur verabreichung von medikamenten mit partiellem einzug des wirkstoffabgabeelements
US11213620B2 (en) 2018-11-01 2022-01-04 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
CA3137360A1 (en) 2019-04-24 2020-10-29 Amgen Inc. Syringe sterilization verification assemblies and methods
WO2021041067A2 (en) 2019-08-23 2021-03-04 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
CA3152547A1 (en) 2019-09-26 2021-04-01 Amgen Inc. Methods of producing antibody compositions
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
EP4229080A1 (de) 2020-10-15 2023-08-23 Amgen Inc. Relative ungepaarte glycane in antikörperherstellungsverfahren
US20240208680A1 (en) 2021-05-21 2024-06-27 Amgen Inc. Method of optimizing a filling recipe for a drug container
AR126089A1 (es) 2021-06-07 2023-09-13 Amgen Inc Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas
CA3233279A1 (en) 2021-10-05 2023-04-13 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2024094457A1 (en) 2022-11-02 2024-05-10 F. Hoffmann-La Roche Ag Method for producing glycoprotein compositions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US4667016A (en) * 1985-06-20 1987-05-19 Kirin-Amgen, Inc. Erythropoietin purification
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1990008822A1 (en) * 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69231467T2 (de) * 1991-05-10 2001-01-25 Genentech, Inc. Auswählen von agonisten und antagonisten von liganden
JPH07503132A (ja) * 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5789192A (en) * 1992-12-10 1998-08-04 Schering Corporation Mammalian receptors for interleukin-10 (IL-10)
US5635388A (en) * 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
US5885574A (en) * 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US6103879A (en) * 1996-06-21 2000-08-15 Axys Pharmaceuticals, Inc. Bivalent molecules that form an activating complex with an erythropoietin receptor

Also Published As

Publication number Publication date
IL114717A0 (en) 1995-11-27
US7081523B2 (en) 2006-07-25
DK0773962T3 (da) 2002-05-21
EP1146056B1 (de) 2007-03-07
EP1146056A1 (de) 2001-10-17
ES2283355T3 (es) 2007-11-01
NZ290689A (en) 1998-07-28
DE69524102T2 (de) 2002-07-04
AU3149995A (en) 1996-02-22
AU697369B2 (en) 1998-10-01
US20070014793A1 (en) 2007-01-18
US6319499B1 (en) 2001-11-20
ATE209218T1 (de) 2001-12-15
EP0773962B1 (de) 2001-11-21
ZA956215B (en) 1997-01-03
DE69535419D1 (de) 2007-04-19
PT1146056E (pt) 2007-05-31
DE69535419T2 (de) 2007-11-08
PT773962E (pt) 2002-05-31
US20080182976A1 (en) 2008-07-31
EP0773962A1 (de) 1997-05-21
WO1996003438A1 (en) 1996-02-08
CN1158134A (zh) 1997-08-27
DE69524102D1 (de) 2002-01-03
CA2195868A1 (en) 1996-02-08
SI0773962T1 (en) 2002-06-30
MX9700553A (es) 1997-05-31
JP3225493B2 (ja) 2001-11-05
ES2168376T3 (es) 2002-06-16
DK1146056T3 (da) 2007-07-02
US5885574A (en) 1999-03-23
US20030215444A1 (en) 2003-11-20
JP2000095800A (ja) 2000-04-04
JPH09508535A (ja) 1997-09-02

Similar Documents

Publication Publication Date Title
DE69535419D1 (de) Antikörper die einen Erythropoietinrezeptor aktivieren
DK0758904T3 (da) Fremgangsmåder og sammensætninger til behandling af glomerulonephritis
ATE248192T1 (de) HUMANISIERTE ANTIKÖRPER DIE AN DAS GLEICHE ANTIGEN WIE ANTIKÖRPER NR-LU-13 BINDEN UND DEREN VERWENDUNG IN ßPRETARGETINGß VERFAHREN
DK0617706T3 (da) Multivalente antigenbindende proteiner
ATE483733T1 (de) Hochaffine humane antikörper gegen tumorantigene
IL189629A0 (en) Compositions containing human ctla-4 antibodies
BR9913912A (pt) Métodos e composições para tratamento de doenças mediadas por receptor
ATE196844T1 (de) Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten
ES2194960T3 (es) N-(2-sustituido-3-(2-aminoetil)-1h-indol-5-il)-amidas como nuevos agonistas de 5-ht1f.
AU2001294541A1 (en) Mammalian genes; related reagents and methods
BR0008688A (pt) Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18
DE60231316D1 (de) VERWENDUNG VON BISPEZIFISCHEN ANTIKÖRPERN GEGEN EINEN AKTIVIERENDEN REZEPTOR FcEpsilonRI UND GEGEN EINEN INHIBIERENDEN REZEPTOR OX2Ra (CD200Ra) ZUR REGULIERUNG DER IMMUNANTWORTEN
DE69630955T2 (de) Immortalisierung bzw. desimmortalisierung von zellen
CA2212150A1 (en) Monoclonal antibodies for human osteogenic cell surface antigens
FI961083A (fi) Rekombinentti-IL4-vasta-aineita, jotka ovat käyttökelpoisia IL-4-välitteisten häiriötilojen hoidossa
DE69929127D1 (de) Bildqualitätsmessung durch die Gegenwart von Blöcken
DE69918413D1 (de) Auswahlverfahren von hla-g exprimierenden tumoren, die durch antikrebsmittel behandelbar sind, und deren verwendungen
DK1181366T3 (da) Mammale receptorproteiner, beslægtede reagenser og fremgangsmåder
DE69333484D1 (de) Umgestaltete monoklonale Antikörper gegen ein Immunglobulinisotyp
PT950056E (pt) N-(piridinilamino) isoindolinas e compostos relacionados
FR2720277B1 (fr) Méthode de traitement des cancers par régulation de la protéine P53.
DE69836096D1 (de) Anti-idiotypische monoklonale antikörper, deren verwendung zur aktiven immuntherapie bösartiger tumoren, und zusammensetzungen die diese enthalten
NZ505085A (en) Pharmaceutical compositions comprising bipapcitide monocarboxylate and/or bipapcitide dicarboxylate for imaging and treating thrombi
BR9610392A (pt) Processo para a preparação de derivados de rodanina substituídos com benzila
ITTO950182V0 (it) Dispositivo di regolazione dell'orientamento di un'antenna pubblicita-ria.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1146056

Country of ref document: EP

REN Ceased due to non-payment of the annual fee